Vera Therapeutics, Inc. (NASDAQ:VERA – Get Free Report) shares were down 5.8% on Tuesday . Needham & Company LLC set a $125.00 price objective on Vera Therapeutics in a research report on Wednesday, July 8th. Get Vera Therapeutics alerts:Read Our Latest Research Report on Vera TherapeuticsVera Therapeutics Stock PerformanceThe firm has a market cap of $2.22 billion, a PE ratio of -5.60 and a beta of 0.92. Insider Activity at Vera TherapeuticsIn related news, CEO Marshall Fordyce sold 46,250 shares of Vera Therapeutics stock in a transaction on Tuesday, July 7th. Further ReadingReceive News & Ratings for Vera Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vera Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.